img

Global Inactivated Influenza Vaccine Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Inactivated Influenza Vaccine Market Insights, Forecast to 2034

Global Inactivated Influenza Vaccine market is expected to reach to US$ 7780 million in 2024, with a positive growth of %, compared with US$ 6990 million in 2022. Backed with the increasing demand from downstream industries, Inactivated Influenza Vaccine industry is evaluated to reach US$ 10610 million in 2029. The CAGR will be 5.3% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Inactivated Influenza Vaccine market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Inactivated Influenza Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


CSL Limited
GSK
Sanofi Pasteur
Viatris
Hualan Biological
AstraZeneca
Sinovac Biotech
Aleph Biomedical
Abbott Laboratories
Novartis International
Changchun Institute of Biological
BCHT
Jiangsu GDK
KM Biologics
Segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine

Segment by Application


Children
Adolescence
Adults
Elderly

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Inactivated Influenza Vaccine plant distribution, commercial date of Inactivated Influenza Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Inactivated Influenza Vaccine introduction, etc. Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Inactivated Influenza Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Inactivated Influenza Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Inactivated Influenza Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Trivalent Influenza Vaccine
1.2.3 Quadrivalent Influenza Vaccine
1.3 Market by Application
1.3.1 Global Inactivated Influenza Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Children
1.3.3 Adolescence
1.3.4 Adults
1.3.5 Elderly
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Inactivated Influenza Vaccine Sales Estimates and Forecasts 2018-2029
2.2 Global Inactivated Influenza Vaccine Revenue by Region
2.2.1 Global Inactivated Influenza Vaccine Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Inactivated Influenza Vaccine Revenue by Region (2018-2024)
2.2.3 Global Inactivated Influenza Vaccine Revenue by Region (2024-2029)
2.2.4 Global Inactivated Influenza Vaccine Revenue Market Share by Region (2018-2029)
2.3 Global Inactivated Influenza Vaccine Sales Estimates and Forecasts 2018-2029
2.4 Global Inactivated Influenza Vaccine Sales by Region
2.4.1 Global Inactivated Influenza Vaccine Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Inactivated Influenza Vaccine Sales by Region (2018-2024)
2.4.3 Global Inactivated Influenza Vaccine Sales by Region (2024-2029)
2.4.4 Global Inactivated Influenza Vaccine Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Inactivated Influenza Vaccine Sales by Manufacturers
3.1.1 Global Inactivated Influenza Vaccine Sales by Manufacturers (2018-2024)
3.1.2 Global Inactivated Influenza Vaccine Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Inactivated Influenza Vaccine in 2022
3.2 Global Inactivated Influenza Vaccine Revenue by Manufacturers
3.2.1 Global Inactivated Influenza Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Inactivated Influenza Vaccine Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Inactivated Influenza Vaccine Revenue in 2022
3.3 Global Key Players of Inactivated Influenza Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Inactivated Influenza Vaccine Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Inactivated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Inactivated Influenza Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Inactivated Influenza Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Inactivated Influenza Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Inactivated Influenza Vaccine Sales by Type
4.1.1 Global Inactivated Influenza Vaccine Historical Sales by Type (2018-2024)
4.1.2 Global Inactivated Influenza Vaccine Forecasted Sales by Type (2024-2029)
4.1.3 Global Inactivated Influenza Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Inactivated Influenza Vaccine Revenue by Type
4.2.1 Global Inactivated Influenza Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Inactivated Influenza Vaccine Forecasted Revenue by Type (2024-2029)
4.2.3 Global Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Inactivated Influenza Vaccine Price by Type
4.3.1 Global Inactivated Influenza Vaccine Price by Type (2018-2024)
4.3.2 Global Inactivated Influenza Vaccine Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Inactivated Influenza Vaccine Sales by Application
5.1.1 Global Inactivated Influenza Vaccine Historical Sales by Application (2018-2024)
5.1.2 Global Inactivated Influenza Vaccine Forecasted Sales by Application (2024-2029)
5.1.3 Global Inactivated Influenza Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Inactivated Influenza Vaccine Revenue by Application
5.2.1 Global Inactivated Influenza Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Inactivated Influenza Vaccine Forecasted Revenue by Application (2024-2029)
5.2.3 Global Inactivated Influenza Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Inactivated Influenza Vaccine Price by Application
5.3.1 Global Inactivated Influenza Vaccine Price by Application (2018-2024)
5.3.2 Global Inactivated Influenza Vaccine Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Inactivated Influenza Vaccine Market Size by Type
6.1.1 US & Canada Inactivated Influenza Vaccine Sales by Type (2018-2029)
6.1.2 US & Canada Inactivated Influenza Vaccine Revenue by Type (2018-2029)
6.2 US & Canada Inactivated Influenza Vaccine Market Size by Application
6.2.1 US & Canada Inactivated Influenza Vaccine Sales by Application (2018-2029)
6.2.2 US & Canada Inactivated Influenza Vaccine Revenue by Application (2018-2029)
6.3 US & Canada Inactivated Influenza Vaccine Market Size by Country
6.3.1 US & Canada Inactivated Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Inactivated Influenza Vaccine Sales by Country (2018-2029)
6.3.3 US & Canada Inactivated Influenza Vaccine Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Inactivated Influenza Vaccine Market Size by Type
7.1.1 Europe Inactivated Influenza Vaccine Sales by Type (2018-2029)
7.1.2 Europe Inactivated Influenza Vaccine Revenue by Type (2018-2029)
7.2 Europe Inactivated Influenza Vaccine Market Size by Application
7.2.1 Europe Inactivated Influenza Vaccine Sales by Application (2018-2029)
7.2.2 Europe Inactivated Influenza Vaccine Revenue by Application (2018-2029)
7.3 Europe Inactivated Influenza Vaccine Market Size by Country
7.3.1 Europe Inactivated Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Inactivated Influenza Vaccine Sales by Country (2018-2029)
7.3.3 Europe Inactivated Influenza Vaccine Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Inactivated Influenza Vaccine Market Size
8.1.1 China Inactivated Influenza Vaccine Sales (2018-2029)
8.1.2 China Inactivated Influenza Vaccine Revenue (2018-2029)
8.2 China Inactivated Influenza Vaccine Market Size by Application
8.2.1 China Inactivated Influenza Vaccine Sales by Application (2018-2029)
8.2.2 China Inactivated Influenza Vaccine Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Inactivated Influenza Vaccine Market Size by Type
9.1.1 Asia Inactivated Influenza Vaccine Sales by Type (2018-2029)
9.1.2 Asia Inactivated Influenza Vaccine Revenue by Type (2018-2029)
9.2 Asia Inactivated Influenza Vaccine Market Size by Application
9.2.1 Asia Inactivated Influenza Vaccine Sales by Application (2018-2029)
9.2.2 Asia Inactivated Influenza Vaccine Revenue by Application (2018-2029)
9.3 Asia Inactivated Influenza Vaccine Sales by Region
9.3.1 Asia Inactivated Influenza Vaccine Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Inactivated Influenza Vaccine Revenue by Region (2018-2029)
9.3.3 Asia Inactivated Influenza Vaccine Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Inactivated Influenza Vaccine Market Size by Type
10.1.1 Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Inactivated Influenza Vaccine Market Size by Application
10.2.1 Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales by Country
10.3.1 Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 CSL Limited
11.1.1 CSL Limited Company Information
11.1.2 CSL Limited Overview
11.1.3 CSL Limited Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 CSL Limited Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 CSL Limited Recent Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Overview
11.2.3 GSK Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 GSK Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi Pasteur
11.3.1 Sanofi Pasteur Company Information
11.3.2 Sanofi Pasteur Overview
11.3.3 Sanofi Pasteur Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Sanofi Pasteur Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Pasteur Recent Developments
11.4 Viatris
11.4.1 Viatris Company Information
11.4.2 Viatris Overview
11.4.3 Viatris Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Viatris Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Viatris Recent Developments
11.5 Hualan Biological
11.5.1 Hualan Biological Company Information
11.5.2 Hualan Biological Overview
11.5.3 Hualan Biological Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Hualan Biological Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Hualan Biological Recent Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Company Information
11.6.2 AstraZeneca Overview
11.6.3 AstraZeneca Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 AstraZeneca Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 AstraZeneca Recent Developments
11.7 Sinovac Biotech
11.7.1 Sinovac Biotech Company Information
11.7.2 Sinovac Biotech Overview
11.7.3 Sinovac Biotech Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Sinovac Biotech Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sinovac Biotech Recent Developments
11.8 Aleph Biomedical
11.8.1 Aleph Biomedical Company Information
11.8.2 Aleph Biomedical Overview
11.8.3 Aleph Biomedical Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Aleph Biomedical Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Aleph Biomedical Recent Developments
11.9 Abbott Laboratories
11.9.1 Abbott Laboratories Company Information
11.9.2 Abbott Laboratories Overview
11.9.3 Abbott Laboratories Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Abbott Laboratories Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Abbott Laboratories Recent Developments
11.10 Novartis International
11.10.1 Novartis International Company Information
11.10.2 Novartis International Overview
11.10.3 Novartis International Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 Novartis International Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Novartis International Recent Developments
11.11 Changchun Institute of Biological
11.11.1 Changchun Institute of Biological Company Information
11.11.2 Changchun Institute of Biological Overview
11.11.3 Changchun Institute of Biological Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Changchun Institute of Biological Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Changchun Institute of Biological Recent Developments
11.12 BCHT
11.12.1 BCHT Company Information
11.12.2 BCHT Overview
11.12.3 BCHT Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 BCHT Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 BCHT Recent Developments
11.13 Jiangsu GDK
11.13.1 Jiangsu GDK Company Information
11.13.2 Jiangsu GDK Overview
11.13.3 Jiangsu GDK Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.13.4 Jiangsu GDK Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Jiangsu GDK Recent Developments
11.14 KM Biologics
11.14.1 KM Biologics Company Information
11.14.2 KM Biologics Overview
11.14.3 KM Biologics Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2018-2024)
11.14.4 KM Biologics Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 KM Biologics Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Inactivated Influenza Vaccine Industry Chain Analysis
12.2 Inactivated Influenza Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Inactivated Influenza Vaccine Production Mode & Process
12.4 Inactivated Influenza Vaccine Sales and Marketing
12.4.1 Inactivated Influenza Vaccine Sales Channels
12.4.2 Inactivated Influenza Vaccine Distributors
12.5 Inactivated Influenza Vaccine Customers
13 Market Dynamics
13.1 Inactivated Influenza Vaccine Industry Trends
13.2 Inactivated Influenza Vaccine Market Drivers
13.3 Inactivated Influenza Vaccine Market Challenges
13.4 Inactivated Influenza Vaccine Market Restraints
14 Key Findings in The Global Inactivated Influenza Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Inactivated Influenza Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Trivalent Influenza Vaccine
Table 3. Major Manufacturers of Quadrivalent Influenza Vaccine
Table 4. Global Inactivated Influenza Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 5. Global Inactivated Influenza Vaccine Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 6. Global Inactivated Influenza Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Inactivated Influenza Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 8. Global Inactivated Influenza Vaccine Revenue Market Share by Region (2018-2024)
Table 9. Global Inactivated Influenza Vaccine Revenue Market Share by Region (2024-2029)
Table 10. Global Inactivated Influenza Vaccine Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Inactivated Influenza Vaccine Sales by Region (2018-2024) & (K Units)
Table 12. Global Inactivated Influenza Vaccine Sales by Region (2024-2029) & (K Units)
Table 13. Global Inactivated Influenza Vaccine Sales Market Share by Region (2018-2024)
Table 14. Global Inactivated Influenza Vaccine Sales Market Share by Region (2024-2029)
Table 15. Global Inactivated Influenza Vaccine Sales by Manufacturers (2018-2024) & (K Units)
Table 16. Global Inactivated Influenza Vaccine Sales Share by Manufacturers (2018-2024)
Table 17. Global Inactivated Influenza Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Inactivated Influenza Vaccine Revenue Share by Manufacturers (2018-2024)
Table 19. Global Key Players of Inactivated Influenza Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 20. Inactivated Influenza Vaccine Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Inactivated Influenza Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Inactivated Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Influenza Vaccine as of 2022)
Table 23. Global Key Manufacturers of Inactivated Influenza Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Inactivated Influenza Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Inactivated Influenza Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Inactivated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 28. Global Inactivated Influenza Vaccine Sales by Type (2024-2029) & (K Units)
Table 29. Global Inactivated Influenza Vaccine Sales Share by Type (2018-2024)
Table 30. Global Inactivated Influenza Vaccine Sales Share by Type (2024-2029)
Table 31. Global Inactivated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Inactivated Influenza Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 33. Global Inactivated Influenza Vaccine Revenue Share by Type (2018-2024)
Table 34. Global Inactivated Influenza Vaccine Revenue Share by Type (2024-2029)
Table 35. Inactivated Influenza Vaccine Price by Type (2018-2024) & (US$/Unit)
Table 36. Global Inactivated Influenza Vaccine Price Forecast by Type (2024-2029) & (US$/Unit)
Table 37. Global Inactivated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 38. Global Inactivated Influenza Vaccine Sales by Application (2024-2029) & (K Units)
Table 39. Global Inactivated Influenza Vaccine Sales Share by Application (2018-2024)
Table 40. Global Inactivated Influenza Vaccine Sales Share by Application (2024-2029)
Table 41. Global Inactivated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Inactivated Influenza Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 43. Global Inactivated Influenza Vaccine Revenue Share by Application (2018-2024)
Table 44. Global Inactivated Influenza Vaccine Revenue Share by Application (2024-2029)
Table 45. Inactivated Influenza Vaccine Price by Application (2018-2024) & (US$/Unit)
Table 46. Global Inactivated Influenza Vaccine Price Forecast by Application (2024-2029) & (US$/Unit)
Table 47. US & Canada Inactivated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 48. US & Canada Inactivated Influenza Vaccine Sales by Type (2024-2029) & (K Units)
Table 49. US & Canada Inactivated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 50. US & Canada Inactivated Influenza Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 51. US & Canada Inactivated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 52. US & Canada Inactivated Influenza Vaccine Sales by Application (2024-2029) & (K Units)
Table 53. US & Canada Inactivated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 54. US & Canada Inactivated Influenza Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 55. US & Canada Inactivated Influenza Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 56. US & Canada Inactivated Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 57. US & Canada Inactivated Influenza Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 58. US & Canada Inactivated Influenza Vaccine Sales by Country (2018-2024) & (K Units)
Table 59. US & Canada Inactivated Influenza Vaccine Sales by Country (2024-2029) & (K Units)
Table 60. Europe Inactivated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 61. Europe Inactivated Influenza Vaccine Sales by Type (2024-2029) & (K Units)
Table 62. Europe Inactivated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 63. Europe Inactivated Influenza Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 64. Europe Inactivated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 65. Europe Inactivated Influenza Vaccine Sales by Application (2024-2029) & (K Units)
Table 66. Europe Inactivated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 67. Europe Inactivated Influenza Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 68. Europe Inactivated Influenza Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 69. Europe Inactivated Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 70. Europe Inactivated Influenza Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 71. Europe Inactivated Influenza Vaccine Sales by Country (2018-2024) & (K Units)
Table 72. Europe Inactivated Influenza Vaccine Sales by Country (2024-2029) & (K Units)
Table 73. China Inactivated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 74. China Inactivated Influenza Vaccine Sales by Type (2024-2029) & (K Units)
Table 75. China Inactivated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 76. China Inactivated Influenza Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 77. China Inactivated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 78. China Inactivated Influenza Vaccine Sales by Application (2024-2029) & (K Units)
Table 79. China Inactivated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 80. China Inactivated Influenza Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 81. Asia Inactivated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 82. Asia Inactivated Influenza Vaccine Sales by Type (2024-2029) & (K Units)
Table 83. Asia Inactivated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 84. Asia Inactivated Influenza Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 85. Asia Inactivated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 86. Asia Inactivated Influenza Vaccine Sales by Application (2024-2029) & (K Units)
Table 87. Asia Inactivated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 88. Asia Inactivated Influenza Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 89. Asia Inactivated Influenza Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 90. Asia Inactivated Influenza Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 91. Asia Inactivated Influenza Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 92. Asia Inactivated Influenza Vaccine Sales by Region (2018-2024) & (K Units)
Table 93. Asia Inactivated Influenza Vaccine Sales by Region (2024-2029) & (K Units)
Table 94. Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales by Type (2018-2024) & (K Units)
Table 95. Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales by Type (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 97. Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue by Type (2024-2029) & (US$ Million)
Table 98. Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales by Application (2018-2024) & (K Units)
Table 99. Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales by Application (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 101. Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue by Application (2024-2029) & (US$ Million)
Table 102. Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 103. Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 105. Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales by Country (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales by Country (2024-2029) & (K Units)
Table 107. CSL Limited Company Information
Table 108. CSL Limited Description and Major Businesses
Table 109. CSL Limited Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 110. CSL Limited Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 111. CSL Limited Recent Developments
Table 112. GSK Company Information
Table 113. GSK Description and Major Businesses
Table 114. GSK Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 115. GSK Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 116. GSK Recent Developments
Table 117. Sanofi Pasteur Company Information
Table 118. Sanofi Pasteur Description and Major Businesses
Table 119. Sanofi Pasteur Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 120. Sanofi Pasteur Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 121. Sanofi Pasteur Recent Developments
Table 122. Viatris Company Information
Table 123. Viatris Description and Major Businesses
Table 124. Viatris Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 125. Viatris Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 126. Viatris Recent Developments
Table 127. Hualan Biological Company Information
Table 128. Hualan Biological Description and Major Businesses
Table 129. Hualan Biological Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 130. Hualan Biological Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 131. Hualan Biological Recent Developments
Table 132. AstraZeneca Company Information
Table 133. AstraZeneca Description and Major Businesses
Table 134. AstraZeneca Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 135. AstraZeneca Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 136. AstraZeneca Recent Developments
Table 137. Sinovac Biotech Company Information
Table 138. Sinovac Biotech Description and Major Businesses
Table 139. Sinovac Biotech Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 140. Sinovac Biotech Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 141. Sinovac Biotech Recent Developments
Table 142. Aleph Biomedical Company Information
Table 143. Aleph Biomedical Description and Major Businesses
Table 144. Aleph Biomedical Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 145. Aleph Biomedical Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 146. Aleph Biomedical Recent Developments
Table 147. Abbott Laboratories Company Information
Table 148. Abbott Laboratories Description and Major Businesses
Table 149. Abbott Laboratories Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 150. Abbott Laboratories Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 151. Abbott Laboratories Recent Developments
Table 152. Novartis International Company Information
Table 153. Novartis International Description and Major Businesses
Table 154. Novartis International Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 155. Novartis International Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 156. Novartis International Recent Developments
Table 157. Changchun Institute of Biological Company Information
Table 158. Changchun Institute of Biological Description and Major Businesses
Table 159. Changchun Institute of Biological Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 160. Changchun Institute of Biological Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 161. Changchun Institute of Biological Recent Developments
Table 162. BCHT Company Information
Table 163. BCHT Description and Major Businesses
Table 164. BCHT Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 165. BCHT Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 166. BCHT Recent Developments
Table 167. Jiangsu GDK Company Information
Table 168. Jiangsu GDK Description and Major Businesses
Table 169. Jiangsu GDK Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 170. Jiangsu GDK Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 171. Jiangsu GDK Recent Developments
Table 172. KM Biologics Company Information
Table 173. KM Biologics Description and Major Businesses
Table 174. KM Biologics Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 175. KM Biologics Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 176. KM Biologics Recent Developments
Table 177. Key Raw Materials Lists
Table 178. Raw Materials Key Suppliers Lists
Table 179. Inactivated Influenza Vaccine Distributors List
Table 180. Inactivated Influenza Vaccine Customers List
Table 181. Inactivated Influenza Vaccine Market Trends
Table 182. Inactivated Influenza Vaccine Market Drivers
Table 183. Inactivated Influenza Vaccine Market Challenges
Table 184. Inactivated Influenza Vaccine Market Restraints
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
List of Figures
Figure 1. Inactivated Influenza Vaccine Product Picture
Figure 2. Global Inactivated Influenza Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Inactivated Influenza Vaccine Market Share by Type in 2022 & 2029
Figure 4. Trivalent Influenza Vaccine Product Picture
Figure 5. Quadrivalent Influenza Vaccine Product Picture
Figure 6. Global Inactivated Influenza Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global Inactivated Influenza Vaccine Market Share by Application in 2022 & 2029
Figure 8. Children
Figure 9. Adolescence
Figure 10. Adults
Figure 11. Elderly
Figure 12. Inactivated Influenza Vaccine Report Years Considered
Figure 13. Global Inactivated Influenza Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Inactivated Influenza Vaccine Revenue 2018-2029 (US$ Million)
Figure 15. Global Inactivated Influenza Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 16. Global Inactivated Influenza Vaccine Revenue Market Share by Region (2018-2029)
Figure 17. Global Inactivated Influenza Vaccine Sales 2018-2029 ((K Units)
Figure 18. Global Inactivated Influenza Vaccine Sales Market Share by Region (2018-2029)
Figure 19. US & Canada Inactivated Influenza Vaccine Sales YoY (2018-2029) & (K Units)
Figure 20. US & Canada Inactivated Influenza Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 21. Europe Inactivated Influenza Vaccine Sales YoY (2018-2029) & (K Units)
Figure 22. Europe Inactivated Influenza Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 23. China Inactivated Influenza Vaccine Sales YoY (2018-2029) & (K Units)
Figure 24. China Inactivated Influenza Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Asia (excluding China) Inactivated Influenza Vaccine Sales YoY (2018-2029) & (K Units)
Figure 26. Asia (excluding China) Inactivated Influenza Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales YoY (2018-2029) & (K Units)
Figure 28. Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue YoY (2018-2029) & (US$ Million)
Figure 29. The Inactivated Influenza Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Inactivated Influenza Vaccine in the World: Market Share by Inactivated Influenza Vaccine Revenue in 2022
Figure 31. Global Inactivated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Inactivated Influenza Vaccine Sales Market Share by Type (2018-2029)
Figure 33. Global Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2029)
Figure 34. Global Inactivated Influenza Vaccine Sales Market Share by Application (2018-2029)
Figure 35. Global Inactivated Influenza Vaccine Revenue Market Share by Application (2018-2029)
Figure 36. US & Canada Inactivated Influenza Vaccine Sales Market Share by Type (2018-2029)
Figure 37. US & Canada Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2029)
Figure 38. US & Canada Inactivated Influenza Vaccine Sales Market Share by Application (2018-2029)
Figure 39. US & Canada Inactivated Influenza Vaccine Revenue Market Share by Application (2018-2029)
Figure 40. US & Canada Inactivated Influenza Vaccine Revenue Share by Country (2018-2029)
Figure 41. US & Canada Inactivated Influenza Vaccine Sales Share by Country (2018-2029)
Figure 42. U.S. Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 43. Canada Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 44. Europe Inactivated Influenza Vaccine Sales Market Share by Type (2018-2029)
Figure 45. Europe Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2029)
Figure 46. Europe Inactivated Influenza Vaccine Sales Market Share by Application (2018-2029)
Figure 47. Europe Inactivated Influenza Vaccine Revenue Market Share by Application (2018-2029)
Figure 48. Europe Inactivated Influenza Vaccine Revenue Share by Country (2018-2029)
Figure 49. Europe Inactivated Influenza Vaccine Sales Share by Country (2018-2029)
Figure 50. Germany Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 51. France Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 52. U.K. Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 53. Italy Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 54. Russia Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 55. China Inactivated Influenza Vaccine Sales Market Share by Type (2018-2029)
Figure 56. China Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2029)
Figure 57. China Inactivated Influenza Vaccine Sales Market Share by Application (2018-2029)
Figure 58. China Inactivated Influenza Vaccine Revenue Market Share by Application (2018-2029)
Figure 59. Asia Inactivated Influenza Vaccine Sales Market Share by Type (2018-2029)
Figure 60. Asia Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2029)
Figure 61. Asia Inactivated Influenza Vaccine Sales Market Share by Application (2018-2029)
Figure 62. Asia Inactivated Influenza Vaccine Revenue Market Share by Application (2018-2029)
Figure 63. Asia Inactivated Influenza Vaccine Revenue Share by Region (2018-2029)
Figure 64. Asia Inactivated Influenza Vaccine Sales Share by Region (2018-2029)
Figure 65. Japan Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 66. South Korea Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 67. China Taiwan Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 68. Southeast Asia Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 69. India Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Inactivated Influenza Vaccine Revenue Share by Country (2018-2029)
Figure 75. Middle East, Africa and Latin America Inactivated Influenza Vaccine Sales Share by Country (2018-2029)
Figure 76. Brazil Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 77. Mexico Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 78. Turkey Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 79. Israel Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 80. GCC Countries Inactivated Influenza Vaccine Revenue (2018-2029) & (US$ Million)
Figure 81. Inactivated Influenza Vaccine Value Chain
Figure 82. Inactivated Influenza Vaccine Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries